The facility will be the site of ITI's process development laboratory that will prepare high quality plasmid DNA for use in vaccine development.

ROCKVILLE, MD, US, November 7, 2013 /EINPresswire.com/ -- Hershey, PA & Rockville, MD November 7th, 2013 – Immunomic Therapeutics, Inc., (“ITI”) a privately-held biotechnology company conducting ground-breaking research & development of vaccines for allergy, infectious disease and cancer, announced that its new facility in the Hershey Center for Applied Research (“HCAR”) is now operational. The HCAR facility will be the site of Immunomic Therapeutics’ process development laboratory that will prepare high quality plasmid DNA for use in vaccine development.

Over the past year, since coming into the new space, ITI has sourced state-of-the art manufacturing equipment while identifying financing and negotiating the best financial arrangements. Further, the Company has identified top-quality bio-process engineering talent in to spearhead the manufacturing operations. Financing for the space has been supported by the state of Pennsylvania some of ITI’s largest shareholders including the Life Sciences Greenhouse of Central Pennsylvania (LSGPA).

The new facility in HCAR, a cutting-edge research park, occupies 1700 sq ft of the 80,000 sq ft facility. HCAR has leveraged local resources and forged partnerships with Penn State University and the Penn State Milton S. Hershey Medical Center. ITI plans to leverage these partnerships for potential collaboration and sourcing opportunities. In the new facility, ITI is deploying Nature Technology Corporation’s HyperGRO™ DNA production process at the new laboratory. This facility houses a plasmid fermentation laboratory to support the production of research-grade plasmid-based vaccines to be used in animal testing of LAMP-vaxTM plasmid-based DNA vaccines, as well as process improvements to the overall DNA plasmid manufacturing process. Thus, vaccines manufactured at Hershey will not only be for internal R&D use but also will support future technical transfer of the production process for commercialization.

ITI’s CEO, Bill Hearl stated, “Now that we have fully stocked the laboratories, brought in the new staff and calibrated the equipment, we are ready to begin producing high quality DNA. We see this facility providing us greater flexibility when it comes to quickly and cost-effectively designing new vaccines as well as improving on the manufacturing process itself.”

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com.


Immunomic Therapeutics, Inc.
1214 Research Boulevard, Suite 2016
Hershey, PA 17036
E-mail: info@immunomix.com
Web: www.immunomix.com


Press Release – Hershey Operational
Issued 11/07/2013

Dr. Bill Hearl
Immunomic Therapeutics, Inc.
1-717-327-1919
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.